Exploring letermovir's effect on immune recovery after cord blood transplantation
Effect of Letermovir Prophylaxis on Cytomegalovirus-specific Immune Reconstitution Post Unrelated Cord Blood Transplantation
This study looks at how a medication called letermovir affects the immune system's recovery from a specific virus after patients receive a cord blood transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | Anhui Provincial Hospital Government |
| Locations | 1 site (Hefei, Anhui) |
| Trial ID | NCT06441669 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how letermovir prophylaxis influences the immune reconstitution specific to cytomegalovirus (CMV) following unrelated umbilical cord blood transplantation (UCBT). It aims to analyze the immune response, particularly focusing on CMV-specific lymphocyte subsets, and to identify potential mechanisms and risk factors associated with late CMV reactivation after stopping letermovir. The study will involve monitoring patients who begin letermovir treatment shortly after their UCBT.
Who should consider this trial
Good fit: Ideal candidates are patients receiving their first unrelated umbilical cord blood transplantation and starting letermovir prophylaxis within 0-28 days post-transplant.
Not a fit: Patients with active CMV DNAemia at the time of letermovir initiation or those involved in other anti-CMV clinical studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance immune recovery and reduce the risk of CMV reactivation in patients undergoing umbilical cord blood transplantation.
How similar studies have performed: While this approach is focused on a specific patient population, similar studies have shown promise in enhancing immune responses and managing CMV reactivation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients are receiving a first unrelated cord blood transplantation (UCBT). * Patients start letemovir prophylaxis within 0-28 days post UCBT. Exclusion Criteria: * Patients having active CMV DNAemia at the time of letermovir initiation. * Patients recruited in a clinical study on an anti-CMV trial.
Where this trial is running
Hefei, Anhui
- Anhui Provincial Hospital — Hefei, Anhui, China (Recruiting)
Study contacts
- Principal investigator: Xiaoyu Zhu, ph.D — The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)
- Study coordinator: Xiaoyu Zhu, ph.D
- Email: xiaoyuz@ustc.edu.cn
- Phone: 15255456091
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.